261 related articles for article (PubMed ID: 24052804)
1. Improved PET imaging of uPAR expression using new (64)Cu-labeled cross-bridged peptide ligands: comparative in vitro and in vivo studies.
Persson M; Hosseini M; Madsen J; Jørgensen TJ; Jensen KJ; Kjaer A; Ploug M
Theranostics; 2013; 3(9):618-32. PubMed ID: 24052804
[TBL] [Abstract][Full Text] [Related]
2. 68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers.
Persson M; Madsen J; Østergaard S; Ploug M; Kjaer A
Nucl Med Biol; 2012 May; 39(4):560-9. PubMed ID: 22172391
[TBL] [Abstract][Full Text] [Related]
3. Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion.
Persson M; Madsen J; Østergaard S; Jensen MM; Jørgensen JT; Juhl K; Lehmann C; Ploug M; Kjaer A
J Nucl Med; 2012 Jan; 53(1):138-45. PubMed ID: 22213823
[TBL] [Abstract][Full Text] [Related]
4. First (18)F-labeled ligand for PET imaging of uPAR: in vivo studies in human prostate cancer xenografts.
Persson M; Liu H; Madsen J; Cheng Z; Kjaer A
Nucl Med Biol; 2013 Jul; 40(5):618-24. PubMed ID: 23602763
[TBL] [Abstract][Full Text] [Related]
5. Urokinase-Type Plasminogen Activator Receptor as a Potential PET Biomarker in Glioblastoma.
Persson M; Nedergaard MK; Brandt-Larsen M; Skovgaard D; Jørgensen JT; Michaelsen SR; Madsen J; Lassen U; Poulsen HS; Kjaer A
J Nucl Med; 2016 Feb; 57(2):272-8. PubMed ID: 26429955
[TBL] [Abstract][Full Text] [Related]
6. Imaging of urokinase-type plasminogen activator receptor expression using a 64Cu-labeled linear peptide antagonist by microPET.
Li ZB; Niu G; Wang H; He L; Yang L; Ploug M; Chen X
Clin Cancer Res; 2008 Aug; 14(15):4758-66. PubMed ID: 18676745
[TBL] [Abstract][Full Text] [Related]
7. Urokinase-Type Plasminogen Activator Receptor (uPAR) Expression and [
Lawaetz M; Binderup T; Christensen A; Juhl K; Lelkaitis G; Lykke E; Knudsen L; von Buchwald C; Kjaer A
Mol Imaging Biol; 2023 Dec; 25(6):1034-1044. PubMed ID: 37749438
[TBL] [Abstract][Full Text] [Related]
8. In vivo detection of urokinase-type plasminogen activator receptor (uPAR) expression in arterial atherogenesis using [
Khare HA; Døssing KBV; Ringgaard L; Christensen E; Urbak L; Sillesen H; Ripa RS; Binderup T; Pedersen SF; Kjaer A
Atherosclerosis; 2022 Jul; 352():103-111. PubMed ID: 35396143
[TBL] [Abstract][Full Text] [Related]
9. Dosimetry of 64Cu-DOTA-AE105, a PET tracer for uPAR imaging.
Persson M; El Ali HH; Binderup T; Pfeifer A; Madsen J; Rasmussen P; Kjaer A
Nucl Med Biol; 2014 Mar; 41(3):290-5. PubMed ID: 24533988
[TBL] [Abstract][Full Text] [Related]
10.
Vats K; Sharma R; Sarma HD; Satpati D; Dash A
Anticancer Agents Med Chem; 2018; 18(9):1289-1294. PubMed ID: 29546835
[TBL] [Abstract][Full Text] [Related]
11. New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts.
Persson M; Rasmussen P; Madsen J; Ploug M; Kjaer A
Nucl Med Biol; 2012 Oct; 39(7):962-9. PubMed ID: 22739362
[TBL] [Abstract][Full Text] [Related]
12. Improved positron emission tomography imaging of glioblastoma cancer using novel
Loft MD; Sun Y; Liu C; Christensen C; Huang D; Kjaer A; Cheng Z
Amino Acids; 2017 Jun; 49(6):1089-1100. PubMed ID: 28316028
[TBL] [Abstract][Full Text] [Related]
13. First-in-human uPAR PET: Imaging of Cancer Aggressiveness.
Persson M; Skovgaard D; Brandt-Larsen M; Christensen C; Madsen J; Nielsen CH; Thurison T; Klausen TL; Holm S; Loft A; Berthelsen AK; Ploug M; Pappot H; Brasso K; Kroman N; Højgaard L; Kjaer A
Theranostics; 2015; 5(12):1303-16. PubMed ID: 26516369
[TBL] [Abstract][Full Text] [Related]
14. uPAR targeted radionuclide therapy with (177)Lu-DOTA-AE105 inhibits dissemination of metastatic prostate cancer.
Persson M; Juhl K; Rasmussen P; Brandt-Larsen M; Madsen J; Ploug M; Kjaer A
Mol Pharm; 2014 Aug; 11(8):2796-806. PubMed ID: 24955765
[TBL] [Abstract][Full Text] [Related]
15. Aptamer imaging with Cu-64 labeled AS1411: preliminary assessment in lung cancer.
Li J; Zheng H; Bates PJ; Malik T; Li XF; Trent JO; Ng CK
Nucl Med Biol; 2014 Feb; 41(2):179-85. PubMed ID: 24373858
[TBL] [Abstract][Full Text] [Related]
16. Targeted imaging of uPAR expression in vivo with cyclic AE105 variants.
Leth JM; Newcombe EA; Grønnemose AL; Jørgensen JT; Qvist K; Clausen AS; Knudsen LBS; Kjaer A; Kragelund BB; Jørgensen TJD; Ploug M
Sci Rep; 2023 Oct; 13(1):17248. PubMed ID: 37821532
[TBL] [Abstract][Full Text] [Related]
17. Safety, Dosimetry, and Tumor Detection Ability of
Skovgaard D; Persson M; Brandt-Larsen M; Christensen C; Madsen J; Klausen TL; Holm S; Andersen FL; Loft A; Berthelsen AK; Pappot H; Brasso K; Kroman N; Højgaard L; Kjaer A
J Nucl Med; 2017 Mar; 58(3):379-386. PubMed ID: 27609788
[TBL] [Abstract][Full Text] [Related]
18. In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems.
Garrison JC; Rold TL; Sieckman GL; Figueroa SD; Volkert WA; Jurisson SS; Hoffman TJ
J Nucl Med; 2007 Aug; 48(8):1327-37. PubMed ID: 17631556
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo evaluation of ⁶⁴Cu-radiolabeled KCCYSL peptides for targeting epidermal growth factor receptor-2 in breast carcinomas.
Kumar SR; Gallazzi FA; Ferdani R; Anderson CJ; Quinn TP; Deutscher SL
Cancer Biother Radiopharm; 2010 Dec; 25(6):693-703. PubMed ID: 21204764
[TBL] [Abstract][Full Text] [Related]
20. Peptide-Based Optical uPAR Imaging for Surgery: In Vivo Testing of ICG-Glu-Glu-AE105.
Juhl K; Christensen A; Persson M; Ploug M; Kjaer A
PLoS One; 2016; 11(2):e0147428. PubMed ID: 26828431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
